{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:31:24Z","timestamp":1787581884810,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005633","name":"Syd\u00e4ntutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009094","name":"Turun Yliopistollisen Keskussairaalan Koulutus- ja Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with prediabetes or diabetes are at increased risk of developing cardiovascular disease and adverse outcomes. First-line coronary computed tomography angiography (CTA) followed by selective use of positron emission tomography (PET) myocardial perfusion imaging is a feasible strategy to diagnose and risk-stratify patients with suspected coronary artery disease (CAD). The aim of the present study was to study whether diabetes changes the relationship of CAD and long-term outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively identified consecutive symptomatic patients who underwent coronary CTA for suspected CAD. In patients with suspected obstructive CAD on CTA, myocardial ischemia was evaluated by <jats:sup>15<\/jats:sup>O-water PET myocardial perfusion imaging. The relationship of the phenotype of CAD and long-term outcome in patients with no diabetes, prediabetes, or type 2 diabetes was investigated. A composite endpoint included all-cause mortality, myocardial infarction (MI), and unstable angina pectoris (UAP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1743 patients were included: 1214 (70%) non-diabetic, 259 (15%) prediabetic, and 270 (16%) type 2 diabetic patients. During 6.43\u00a0years of median follow-up, 164 adverse events occurred (106 deaths, 41 MIs, 17 UAPs). The prevalence of normal coronary arteries on CTA was highest in the non-diabetic patients (39%). The prevalence of hemodynamically significant CAD (abnormal perfusion) increased from 14% in non-diabetic patients to 20% in prediabetic and 27% in diabetic patients. The event rate was lowest in patients with normal coronary arteries and highest in patients with concomitant type 2 diabetes and hemodynamically significant CAD (annual event rate 0.2% vs. 4.7%). However, neither prediabetes nor diabetes were independent predictors of the composite adverse outcome after adjustment for the clinical risk factors and imaging findings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Coronary CTA followed by selective downstream use of PET myocardial perfusion imaging predicts long-term outcome similarly in non-diabetic and diabetic patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01850-3","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T04:07:28Z","timestamp":1685506048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The impact of diabetes on the relationship of coronary artery disease and outcome: a study using multimodality imaging"],"prefix":"10.1186","volume":"22","author":[{"given":"Matias","family":"M\u00e4enp\u00e4\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iida","family":"Kujala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa","family":"Harjulahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iida","family":"Stenstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wail","family":"Nammas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhani","family":"Knuuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Saraste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teemu","family":"Maaniitty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"issue":"9733","key":"1850_CR1","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Kondapally Seshasai SR, Gobin R, Kaptoge S, di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215\u201322.","journal-title":"Lancet"},{"issue":"2","key":"1850_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"18","key":"1850_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","volume":"373","author":"M Tancredi","year":"2015","unstructured":"Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbj\u00f6rnsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720\u201332.","journal-title":"N Engl J Med"},{"issue":"370","key":"1850_CR4","first-page":"848","volume":"15","author":"X Cai","year":"2020","unstructured":"Cai X, Zhang Y, Li M, Wu JHY, Mai L, Li J, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;15(370):848\u20139.","journal-title":"BMJ"},{"issue":"3","key":"1850_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2019","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. ESC Guidelines for the diagnosis and management of chronic coronary syndromesThe Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;41(3):407\u201377.","journal-title":"Eur Heart J."},{"key":"1850_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2019-315183","author":"JM Tarkin","year":"2020","unstructured":"Tarkin JM, \u0106orovi\u0107 A, Wall C, Gopalan D, Rudd JHF. Positron emission tomography imaging in cardiovascular disease. Heart 2020;106(22):1712\u201318. https:\/\/doi.org\/10.1136\/heartjnl-2019-315183.","journal-title":"Heart"},{"issue":"1117","key":"1850_CR7","doi-asserted-by":"publisher","first-page":"20200780","DOI":"10.1259\/bjr.20200780","volume":"94","author":"MA Daubert","year":"2021","unstructured":"Daubert MA, Tailor T, James O, Shaw LJ, Douglas PS, Koweek L. Multimodality cardiac imaging in the 21st century: evolution, advances and future opportunities for innovation. Br J Radiol. 2021;94(1117):20200780.","journal-title":"Br J Radiol."},{"issue":"4","key":"1850_CR8","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1007\/s12350-021-02533-w","volume":"28","author":"R Assante","year":"2021","unstructured":"Assante R, Mainolfi CG, Zampella E, Gaudieri V, Nappi C, Mannarino T, et al. Relation between myocardial blood flow and cardiac events in diabetic patients with suspected coronary artery disease and normal myocardial perfusion imaging. J Nucl Cardiol. 2021;28(4):1222\u201333.","journal-title":"J Nucl Cardiol"},{"issue":"15","key":"1850_CR9","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.112.120402","volume":"126","author":"VL Murthy","year":"2012","unstructured":"Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. 2012;126(15):1858\u201368.","journal-title":"Circulation"},{"issue":"12","key":"1850_CR10","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1093\/eurheartj\/ehr047","volume":"32","author":"AP Pazhenkottil","year":"2011","unstructured":"Pazhenkottil AP, Nkoulou RN, Ghadri JR, Herzog BA, Buechel RR, K\u00fcest SM, et al. Prognostic value of cardiac hybrid imaging integrating single-photon emission computed tomography with coronary computed tomography angiography. Eur Heart J. 2011;32(12):1465\u201371.","journal-title":"Eur Heart J"},{"issue":"6","key":"1850_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.amjmed.2021.12.010","volume":"135","author":"T Alnabelsi","year":"2022","unstructured":"Alnabelsi T, Ahmed AI, Han Y, Al Rifai M, Nabi F, Cainzos-Achirica M, et al. Added prognostic value of plaque burden to computed tomography angiography and myocardial perfusion imaging in patients with diabetes. Am J Med. 2022;135(6):761-768.e7.","journal-title":"Am J Med"},{"issue":"11","key":"1850_CR12","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jcmg.2016.10.025","volume":"10","author":"T Maaniitty","year":"2017","unstructured":"Maaniitty T, Stenstr\u00f6m I, Bax JJ, Uusitalo V, Ukkonen H, Kajander S, et al. prognostic value of coronary CT angiography with selective PET perfusion imaging in coronary artery disease. JACC Cardiovasc Imaging. 2017;10(11):1361\u201370.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"1850_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jcct.2014.07.003","volume":"8","author":"J Leipsic","year":"2014","unstructured":"Leipsic J, Abbara S, Achenbach S, Cury R, Earls JP, Mancini GBJ, et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2014;8(5):342\u201358.","journal-title":"J Cardiovasc Comput Tomogr"},{"issue":"14","key":"1850_CR14","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.jacc.2014.05.069","volume":"64","author":"I Danad","year":"2014","unstructured":"Danad I, Uusitalo V, Kero T, Saraste A, Raijmakers PG, Lammertsma AA, et al. Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease: cutoff values and diagnostic accuracy of quantitative [(15)O]H2O PET imaging. J Am Coll Cardiol. 2014;64(14):1464\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1850_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","volume":"314","author":"E di Angelantonio","year":"2015","unstructured":"di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52\u201360.","journal-title":"JAMA"},{"issue":"11","key":"1850_CR16","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1007\/s00259-021-05349-5","volume":"48","author":"F Caobelli","year":"2021","unstructured":"Caobelli F, Haaf P, Haenny G, Pfisterer M, Zellweger MJ. Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial. Eur J Nucl Med Mol Imaging. 2021;48(11):3512\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1850_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/1479164120941809","author":"C Gyldenkerne","year":"2020","unstructured":"Gyldenkerne C, Olesen KKW, Thrane PG, Madsen M, Thim T, W\u00fcrtz M, et al. Diabetes is not a risk factor for myocardial infarction in patients without coronary artery disease: a study from the Western Denmark Heart Registry. Diab Vasc Dis Res 2020;17(4):1479164120941809. https:\/\/doi.org\/10.1177\/1479164120941809.","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"1850_CR18","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.2337\/dc16-0281","volume":"39","author":"C Celeng","year":"2016","unstructured":"Celeng C, Maurovich-Horvat P, Ghoshhajra BB, Merkely B, Leiner T, Takx RAP. Prognostic value of coronary computed tomography angiography in patients with diabetes: a meta-analysis. Diabetes Care. 2016;39(7):1274\u201380.","journal-title":"Diabetes Care"},{"issue":"5","key":"1850_CR19","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s12350-019-01846-1","volume":"27","author":"W Acampa","year":"2019","unstructured":"Acampa W, Assante R, Zampella E, Petretta M, Cuocolo A. Myocardial perfusion imaging for diabetes: Key points from the evidence and clinical questions to be answered. J Nucl Cardiol. 2019;27(5):1569\u201377.","journal-title":"J Nucl Cardiol."},{"issue":"3","key":"1850_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2337\/diaclin.29.3.116","volume":"3","author":"MJ Fowler","year":"2011","unstructured":"Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2011;3(3):116\u201322.","journal-title":"Clin Diabetes"},{"issue":"4","key":"1850_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/cvr\/cvaa006","volume":"116","author":"CN Bairey Merz","year":"2020","unstructured":"Bairey Merz CN, Pepine CJ, Shimokawa H, Berry C. Treatment of coronary microvascular dysfunction. Cardiovasc Res. 2020;116(4):856\u201370.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"1850_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/heartjnl-2021-319773","volume":"108","author":"BL N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard BL, Gaur S, Fairbairn TA, Douglas PS, Jensen JM, Patel MR, et al. Original research: prognostic value of coronary computed tomography angiographic derived fractional flow reserve: a systematic review and meta-analysis. Heart. 2022;108(3):194.","journal-title":"Heart"},{"issue":"6","key":"1850_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1403494812456637","volume":"40","author":"R Sund","year":"2012","unstructured":"Sund R. Quality of the finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40(6):505\u201315.","journal-title":"Scand J Public Health"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01850-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T19:02:27Z","timestamp":1685559747000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01850-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1850"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01850-3","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"assertion":[{"value":"4 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complies with the Declaration of Helsinki. The Ethics Committee of the Hospital District of Southwest Finland approved the study protocol and waived the need for written informed consent for retrospective observational data evaluation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer-Ingelheim, Pfizer and Merck, outside of the submitted work. Dr. Saraste received consultancy fees from Amgen and Astra Zeneca, Boehringer Ingelheim and Pfizer, and speaker fees from Abbott, Astra Zeneca, and Bayer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}